Inclusion Criteria:  Signed informed consent form Able to comply with the study protocol, in the investigator's judgment Affiliation to the social security system Completed the treatment period of Roche-sponsored ocrelizumab trial (CONSONANCE) and who in the opinion of the investigator may benefit from treatment with ocrelizumab. Only patients enrolled under Protocol version 1 (approval date: 18 February 2018) will be eligible. Meet re-treatment criteria with ocrelizumab (please see section 6.11) Patients who became pregnant by chance between the last visit of the CONSONANCE study and screening of this study, as confirmed by pregnancy tests at screening, will enter the study but will only re-start treatment with ocrelizumab after birth or after breastfeeding is stopped, as per re-treatment criteria in section 6.11  Women of childbearing potential* (WOCBP):  Must have a negative urine pregnancy test at Visit 1 (Screening) and Visit 2 (Baseline) Must agree to remain abstinent or use an acceptable birth control method during the treatment period and for at least 6 months or longer after the final dose of ocrelizumab, as applicable in the ocrelizumab package leaflet. The following contraceptive methods are considered acceptable (failure rate >1% [Clinical Trial Facilitation Group (CTFG)]): (1) progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action; (2) male or female condom with or without spermicide; (3) cap, diaphragm, or sponge with spermicide; (4) combination of male condom with cap, diaphragm, or sponge with spermicide (double-barrier method). Birth control methods that are highly effective (i.e. failure rate <1% [CTFG]) may also be used but are not required, and include: (1) oral, intravaginal or transdermal combined hormonal contraception associated with inhibition of ovulation; (2) oral, injectable or implantable progestogen-only hormonal contraception associated with inhibition of ovulation; (3) intrauterine device; (4) intrauterine hormone-releasing system; (5) bilateral tubal occlusion; (6) vasectomized partner; (7) sexual abstinence.  Exclusion Criteria:  Hypersensitivity to ocrelizumab or any of its excipients Patients in a severely immunocompromised state, until the condition resolves Evidence of any adverse event (AE) potentially attributable to ocrelizumab, for which the local label recommends permanent discontinuation Existence of a contra-indication as per the Summary of Product Characteristics (SmPC) Prohibited concomitant medication as specified in section 6.7 Patients intending to become pregnant during the study or within 6 months after the last dose of the study drug in CONSONANCE Patients who had early ocrelizumab discontinuation in CONSONANCE (exemption made for treatment discontinuation due to unplanned pregnancy and breastfeeding for patients who continued clinical study assessments in CONSONANCE)